Small white tablets in a clear glass dish on a pale surface
DoseRoutine Enclomiphene — Small white tablets in a clear glass dish on a pale surface. Original DoseRoutine photography.
hormoneNot FDA-approvedPrescription only (US)Not FDA-approved; the new drug application was not grantedAvailable only through compounding pharmaciesProhibited in sport (WADA S4)

EnclomipheneBenefits, Dosage & Interactions

Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) that is being investigated for its potential use in treating secondary hypogonadism in men. It is an isomer of clomiphene citrate, a drug that has been used for decades to induce ovulation in women.

How much Enclomiphene do people take?

The pooled trials used 12.5 mg and 25 mg daily. Route reported: Oral. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Enclomiphene — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

See the full reported protocol and its sources

Researched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.

Evidence: Moderate — Covered by a systematic review, without regulatory approval.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence

Covered by a systematic review, without regulatory approval.

Chemical structure of Enclomiphene (PubChem CID 1548953)
Structure via PubChem
Plasma half-life
~10 h
Default unit
mg

What published protocols report

Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.

Reported amounts
The pooled trials used 12.5 mg and 25 mg daily[1][2]
Route studied
Oral[1][2]
Frequency
Once daily[1][2]
Cycle length
Three to six months across the pooled trials[1][2]
Half-life
Approximately 10 hours for the trans (enclomiphene) isomer[1][2]
Storage
Room temperature, protected from light[1][2]

Reported for Enclomiphene in the cited sources. Published ranges are not dosing advice.

References & evidence

Documents the Enclomiphene entry is written from. Each number matches an inline marker above.

  1. [1]Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trialsHohl A, et al. · Archives of Endocrinology and Metabolism · 2025 · Peer-reviewed · PMID 41066380
  2. [2]Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysisTienforti D, Castellini C, Di Giulio F, et al. · Andrology · 2023 · Peer-reviewed · PMID 36604313

References & Evidence

Sources on this page that document Enclomiphene dosing, timing and safety.

  1. [1]National Center for Biotechnology Information View source

Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.

What is Enclomiphene studied for?

What is Enclomiphene?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.

Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) that is being investigated for its potential use in treating secondary hypogonadism in men. It is an isomer of clomiphene citrate, a drug that has been used for decades to induce ovulation in women. While clomiphene citrate is a mixture of two isomers, enclomiphene and zuclomiphene, enclomiphene is thought to be the primary therapeutically active component responsible for stimulating gonadotropin release. In men, secondary hypogonadism is characterized by low testosterone levels due to impaired testicular function resulting from abnormal pituitary or hypothalamic signaling. Enclomiphene aims to address this by modulating estrogen receptors, ultimately leading to increased endogenous testosterone production. Unlike traditional testosterone replacement therapy (TRT), which introduces exogenous testosterone and can suppress natural production, enclomiphene works by stimulating the body's own hormone-producing mechanisms. This distinction is significant for men who wish to maintain their own testicular function and fertility. Enclomiphene is typically administered orally.

What does the research say about Enclomiphene?

Tap a section to expand.

Enclomiphene acts as a selective estrogen receptor modulator (SERM). Its primary mechanism of action in men involves antagonism of estrogen receptors in the hypothalamus and pituitary gland. The hypothalamus detects circulating estrogen levels and, in response to lower perceived estrogen, releases gonadotropin-releasing hormone (GnRH). GnRH then stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH, in turn, stimulates the Leydig cells in the testes to produce testosterone, while FSH supports spermatogenesis. By blocking estrogen's negative feedback at these critical points, enclomiphene effectively "tricks" the hypothalamus and pituitary into believing that estrogen levels are low, thereby increasing the secretion of LH and FSH, which subsequently leads to an increase in endogenous testosterone production. This process helps to restore a more normal hormonal balance in men with secondary hypogonadism, promoting natural testosterone synthesis without directly introducing exogenous hormones. (Source: PubChem, DrugBank)

Source for this section: Sources for How does Enclomiphene work?: Jumps to this entry in the sources and references list at the end of the page.

The primary potential benefit of enclomiphene for men with secondary hypogonadism is an increase in endogenous testosterone levels. This increase may lead to improvements in various symptoms associated with low testosterone, such as: * **Improved Libido:** Low testosterone is often linked to decreased sex drive, and restoring testosterone to healthy levels can alleviate this. * **Enhanced Energy Levels:** Many men with hypogonadism experience fatigue, and increased testosterone may help boost energy and reduce tiredness. * **Improved Mood:** Low testosterone has been associated with mood disturbances, including irritability and mild depression. Normalizing testosterone levels may help stabilize mood. * **Increased Muscle Mass and Strength:** Testosterone plays a crucial role in muscle protein synthesis. Higher testosterone levels can support muscle growth and strength, particularly when combined with resistance training. This aligns with enclomiphene's classification under the 'muscle' goal tag. * **Improved Bone Density:** Testosterone contributes to maintaining bone mineral density. Increasing testosterone may help reduce the risk of osteoporosis. * **Maintenance of Testicular Function and Fertility:** Unlike external testosterone replacement therapy, enclomiphene aims to stimulate the testes directly, which can help preserve natural testicular function and sperm production. This is a significant advantage for men who are concerned about fertility. (Source: DrugBank, investigational studies) It is important to note that while these benefits are observed in studies, individual responses can vary. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

Clinical trials and research studies have explored the efficacy and safety of enclomiphene in men with secondary hypogonadism. A review of studies indicates that enclomiphene reliably increases serum total testosterone and LH levels in men with low testosterone. For example, a controlled study, as referenced by an FDA label for a related compound, demonstrated that enclomiphene significantly increased total testosterone levels above the lower limit of the normal range. These increases were often accompanied by improvements in symptoms associated with hypogonadism. Furthermore, some studies have shown that enclomiphene can increase sperm concentration and motility, suggesting a potential role in preserving fertility in hypogonadal men, a key differentiator from exogenous testosterone treatments. More specific details regarding these studies, including their methodologies and patient populations, can be found in peer-reviewed scientific literature and regulatory submissions. (Source: FDA label (related compounds), PubChem, scientific literature).

While generally considered to be well-tolerated, enclomiphene may cause some side effects, which can vary in severity and frequency among individuals. Common side effects reported in clinical trials include: * **Headache:** A frequently reported side effect. * **Nausea:** Some users may experience stomach upset. * **Fatigue:** Paradoxically, while aimed at improving energy, some individuals might experience fatigue. * **Dizziness:** Occasional reports of lightheadedness. * **Hot Flashes:** Similar to effects seen with other SERMs, hot flashes can occur due to estrogen receptor modulation. * **Acne:** Hormonal changes can sometimes trigger or worsen acne. * **Visual Disturbances:** Although less common, some individuals have reported blurred vision or other visual symptoms. This warrants immediate medical attention if experienced. * **Mood Changes:** Shifts in mood, including irritability or anxiety, have been noted in some cases. Less common but more serious side effects may include changes in liver enzymes, though these are typically transient. It is crucial to report any persistent or concerning side effects to a healthcare professional. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

Individuals considering enclomiphene should be aware of several warnings and precautions. Enclomiphene is generally contraindicated in individuals with known hypersensitivity to the drug or any of its components. It should be used with caution in men with existing liver impairment, as liver function tests may need to be monitored. Patients with a history of visual disturbances should be closely monitored, and any new visual symptoms should prompt immediate discontinuation and medical evaluation. Hormone-sensitive conditions, such as prostate cancer, should be ruled out before initiating enclomiphene therapy, as modulating testosterone levels could potentially affect such conditions. Regular monitoring of testosterone, LH, and FSH levels, as well as general health markers, is recommended during treatment to assess efficacy and safety. Given its impact on hormonal axes, enclomiphene is a controlled compound, meaning its use must be under the direct supervision and prescription of a licensed clinician. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

Enclomiphene is contraindicated in several circumstances to ensure patient safety. These include: * **Known Hypersensitivity:** Individuals with a documented allergic reaction to enclomiphene or any of its excipients should not use this compound. * **Pregnancy and Lactation:** While primarily for men, it is contraindicated in women who are or may become pregnant, or who are breastfeeding, due to potential adverse effects on fetal development or infants. This is consistent with its estrogen receptor modulator activity. * **Unexplained Vaginal Bleeding:** In women, and as a component of clomiphene citrate, it is contraindicated in cases of unexplained vaginal bleeding. * **Liver Disease or Impairment:** Individuals with active liver disease or significant liver dysfunction should avoid enclomiphene due to potential hepatotoxicity. * **Adrenal or Thyroid Dysfunction:** Enclomiphene is contraindicated in individuals with uncontrolled adrenal or thyroid gland dysfunction, as it can interfere with other hormonal pathways. * **Hormone-Dependent Tumors:** Any known or suspected hormone-dependent tumors, such as prostate cancer, are a contraindication due to the direct or indirect influence on hormone levels within the body. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

Due to its mechanism of action and effects on hormone levels, enclomiphene should be used with caution, if at all, when combined with certain other compounds. Specific interactions may include: * **Other Hormone-Modulating Therapies:** Concomitant use with other drugs that significantly alter testosterone, estrogen, or gonadotropin levels (e.g., exogenous testosterone replacement, aromatase inhibitors, other SERMs) could lead to unpredictable hormonal imbalances or exacerbated side effects. Such combinations would require very careful monitoring and clinician oversight. * **Drugs Metabolized by the Liver:** Although enclomiphene's primary metabolism pathways are not explicitly detailed as major drug interaction concerns, caution is always advised when combining with other compounds that place a significant burden on hepatic metabolism, particularly in individuals with pre-existing liver conditions. * **Drugs Affecting Vision:** Given the potential for visual disturbances with enclomiphene, co-administration with other medications known to cause ocular side effects should be approached with caution and under medical guidance. Always inform your healthcare provider about all medications, supplements, and herbal products you are currently taking to avoid potential adverse interactions. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.

Enclomiphene is typically administered orally. The timing and frequency of administration are user-directed and must be set by a licensed clinician based on individual patient needs, hormonal profiles, and treatment goals. Dosing regimens can vary, and continuous daily dosing or cyclical regimens may be used. It is essential to follow the specific instructions provided by your clinician and to take enclomiphene consistently at the prescribed times to maintain stable drug levels and optimize therapeutic effects. Enclomiphene can generally be taken with or without food, but specific instructions from your clinician should always be followed.

Source for this section: Sources for When should you take Enclomiphene?: Jumps to this entry in the sources and references list at the end of the page.

Put it into practice

Reading about Enclomiphene is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.

What interacts with Enclomiphene?

Documented interactions for Enclomiphene: the other compound, the severity and confidence of the interaction, what happens, and what to do.
Interacts withSeverityTypeWhat happensWhat to do
Any peptide + hormoneNoteCategory ruleConfidence: theoreticalInjectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pendingTrack bloodwork with a provider; don't assume combinations are neutral.

Frequently asked questions about Enclomiphene

The main difference is that enclomiphene stimulates the body to produce its own testosterone by increasing LH and FSH, thereby preserving natural testicular function and potentially fertility. TRT, conversely, introduces external testosterone, which can suppress the body's natural production and may lead to testicular atrophy and impaired fertility.

While enclomiphene can improve sperm parameters in some men with secondary hypogonadism, making it potentially beneficial for fertility, it is not universally approved specifically as a fertility treatment. Its primary investigational use is for increasing testosterone levels in men with secondary hypogonadism. Fertility outcomes are often a beneficial side effect of normalized endocrine function rather than its direct, approved indication.

Patients typically begin to see an increase in testosterone levels within a few weeks of starting enclomiphene therapy, with more significant symptomatic improvements potentially taking several weeks to months. Regular blood tests are usually conducted to monitor hormonal responses and guide treatment adjustments.

Long-term safety data for enclomiphene is still being gathered through ongoing research and clinical trials. While it has shown promising safety profiles in studies to date, the decision for long-term use should always be made in consultation with a licensed clinician, taking into account individual health status and risk factors.

Enclomiphene is primarily developed and studied for use in men with secondary hypogonadism. Its use in women, particularly due to its estrogen receptor modulating effects, would be highly specialized and typically restricted to specific fertility treatments within the broader clomiphene citrate context, under strict medical supervision. It is contraindicated in pregnant or lactating women.

As a hormone, Enclomiphene can overlap with other supplements, prescription medicines, hormones and peptides. With a reported plasma half-life near 10 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Enclomiphene with no sign-up.

The reported plasma half-life is about 10 hours, which is what drives how often it is redosed. It is a controlled substance in some jurisdictions, so the prescribed amount is the only appropriate one. Amounts for this hormone vary by protocol, formulation and individual response, so follow the dose your clinician or the product label specifies.

"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Enclomiphene. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.

With a plasma half-life near 10 hours, once-daily dosing is the usual pattern for Enclomiphene. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps

With a plasma half-life near 10 hours, a single missed dose of Enclomiphene usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.

For Enclomiphene the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.

The pooled trials used 12.5 mg and 25 mg daily. Route reported: Oral. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Enclomiphene — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

Which studies looked at Enclomiphene?

Peer-reviewed research indexed in PubMed. Each entry links to the original record.

  1. 1.Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials(opens PubMed in a new tab)Arch Endocrinol Metab · 2025 · PMID 41066380 · https://pubmed.ncbi.nlm.nih.gov/41066380/
  2. 2.Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.(opens PubMed in a new tab)BJU international · 2013 · PMID 23875626 · https://pubmed.ncbi.nlm.nih.gov/23875626/
  3. 3.Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men(opens PubMed in a new tab)IDrugs · 2009 · PMID 19204885 · https://pubmed.ncbi.nlm.nih.gov/19204885/
  4. 4.Enclomiphene citrate for the treatment of secondary male hypogonadism(opens PubMed in a new tab)Expert Opin Pharmacother · 2016 · PMID 27337642 · https://pubmed.ncbi.nlm.nih.gov/27337642/
  5. 5.Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone(opens PubMed in a new tab)Fertil Steril · 2014 · PMID 25044085 · https://pubmed.ncbi.nlm.nih.gov/25044085/

Sources cited on this page

Specific documents referenced by the numbered markers above. Each number matches the marker in the text.

  1. PubChem CID 1548953(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/1548953

Verify at

Publisher search links for Enclomiphene. These are places to check the information — they are not citations, so they are not numbered.

DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.

What is the short answer on Enclomiphene?

Plain-text summary, safe to quote verbatim:

Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) that is being investigated for its potential use in treating secondary hypogonadism in men. It is an isomer of clomiphene citrate, a drug that has been used for decades to induce ovulation in women.
Source: DoseRoutine — https://doseroutine.com/library/enclomiphene

Enclomiphene cheat sheet

DoseRoutine cheat sheet · Hormone

Enclomiphene

Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) that is being investigated for its potential use in treating secondary hypogonadism in men. It is an isomer of clomiphene citrate, a drug that has been used for decades to induce ovulation in women.

Evidence

Moderate

Covered by a systematic review, without regulatory approval.

Studied range

The pooled trials used 12.5 mg and 25 mg daily

Route

Oral

Frequency studied

Once daily

Half-life

~10 h

Storage

Room temperature, protected from light

Not FDA-approvedPrescription only (US)Not FDA-approved; the new drug application was not grantedAvailable only through compounding pharmaciesProhibited in sport (WADA S4)TestosteroneBrainBone JointMuscle

Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/enclomiphene

Cite this page

Using this in an article, AI answer, or research note? Please attribute:

DoseRoutine. (2026). Enclomiphene — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/enclomiphene
Canonical URL

What compounds are similar to Enclomiphene?

Others in the hormone category or studied for the same goals.

Which goals is Enclomiphene used for?

Other compounds studied for the same benefits as Enclomiphene.

Continue exploring

See every compound DoseRoutine catalogs for these goals.

Track Enclomiphene in DoseRoutine

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Sign up free →

Latest research from DoseRoutine

Browse all DoseRoutine research updates

Track Enclomiphene in your own routine

Add Enclomiphene to your stack, get reminders at the right times, and see interaction notes with everything else you take. Free to start — no card needed.